LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
Rhea-AI Summary
LIXTE Biotechnology (Nasdaq: LIXT) will participate at the DealFlow Discovery Conference in Atlantic City, New Jersey on January 28-29, 2026. CEO Geordan Pursglove is scheduled to hold one-on-one investor meetings at The Borgata Hotel, Casino & Spa. The company is clinical-stage and advancing LB-100, a PP2A inhibitor. Investors may register or request meetings via the conference registration page.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: AKTX +0.57%, QTTB +1.41%, ALLR +0.85% versus BOLD -2.36% and PPCB -15.77%, indicating stock-specific factors rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Trial expansion update | Positive | -1.9% | Ovarian clear cell cancer trial enrollment doubled from 21 to 42 patients. |
| Dec 18 | Equity offering | Negative | -1.0% | Registered direct offering to raise $4.3M via units and warrants. |
| Dec 08 | Oncology strategy shift | Positive | +7.2% | Acquisition of Liora Technologies and LiGHT radiotherapy platform. |
| Dec 03 | Platform expansion | Positive | +3.5% | Multi-modal oncology platform update and Liora acquisition details. |
| Dec 03 | Treatment amplifier focus | Positive | +3.5% | Progress update on LB-100 as amplifier and key partnerships. |
Recent strategic and trial updates have generally been followed by positive price reactions, while trial expansion and financing updates saw mild declines.
Over the last two months, LIXT reported several oncology strategy and asset expansion updates, including moving toward a multi‑modal platform and advancing LB‑100 combinations with major partners. On December 3, 2025, multi‑modal and treatment amplifier positioning updates each coincided with +3.45% moves. A strategy piece on December 8, 2025 saw a +7.16% reaction. By contrast, the ovarian cancer trial expansion on December 23, 2025 and the $4.3 million offering on December 18, 2025 were followed by modest declines.
Market Pulse Summary
This announcement highlights LIXTE’s plan to engage investors at a January 28–29, 2026 conference, offering additional visibility around its LB-100 program. Recent months featured trial expansion in clear cell ovarian cancer and a shift toward a multi-modal oncology platform, alongside prior equity financing activity. Investors may monitor future clinical readouts, financing decisions, and strategic updates as more material drivers than this conference participation itself.
Key Terms
protein phosphatase 2A (PP2A) medical
AI-generated analysis. Not financial advice.
BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today announced the Company will participate at the DealFlow Discovery Conference in Atlantic City, New Jersey, January 28-29, 2026. Geordan Pursglove, LIXTE’s Chief Executive Officer, will conduct one-on-one meetings with investors during the conference.
The conference will be held at The Borgata Hotel, Casino & Spa, 1 Borgata Way. To register or schedule a one-on-one meeting, please visit https://dealflowdiscoveryconference.com/registration/
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at www.lixte.com.
Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.
For more information about LIXTE, contact:
info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
FAQ
When will LIXTE (LIXT) attend the DealFlow Discovery Conference?
Who from LIXTE will meet investors at the DealFlow Discovery Conference?
Where is the DealFlow Discovery Conference being held for LIXTE meetings?
How can investors schedule a one-on-one meeting with LIXTE at the conference?
What program is LIXTE advancing that investors may ask about at the conference?
Is LIXTE a public company and what is its ticker symbol?
